Skip to main content
  • AACR Publications
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

  • Register
  • Log in
Advertisement

Main menu

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Focus on Computer Resources
    • 75th Anniversary
    • Meeting Abstracts
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • OnlineFirst
    • Editors' Picks
    • Citations
    • Author/Keyword
  • News
    • Cancer Discovery News
  • AACR Publications
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

User menu

  • Register
  • Log in

Search

  • Advanced search
Cancer Research
Cancer Research

Advanced Search

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Focus on Computer Resources
    • 75th Anniversary
    • Meeting Abstracts
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • OnlineFirst
    • Editors' Picks
    • Citations
    • Author/Keyword
  • News
    • Cancer Discovery News
Experimental and Molecular Therapeutics

Abstract #4528: The effect of conformational dynamics of cisplatin- and oxaliplatin-DNA Adducts on binding of DNA damage recognition proteins such as HMGB1

Srinivas Ramachandran, Brenda Temple, Nikolay Dokholyan and Stephen Chaney
Srinivas Ramachandran
Univ. of North Carolina, Chapel Hill, NC
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Brenda Temple
Univ. of North Carolina, Chapel Hill, NC
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Nikolay Dokholyan
Univ. of North Carolina, Chapel Hill, NC
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Stephen Chaney
Univ. of North Carolina, Chapel Hill, NC
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
DOI:  Published May 2009
  • Article
  • Info & Metrics
Loading
AACR Annual Meeting-- Apr 18-22, 2009; Denver, CO

Abstract

The DNA binding protein domain HMGB1a binds to cisplatin (CP)-GG DNA adducts with 20-fold greater affinity than to oxaliplatin (OX)-GG adducts when those adducts are in the TGGA sequence context. A thorough understanding of this differential binding affinity might lead to better understanding of the differences in efficacy, toxicity and mutagenesis of these platinum anticancer drugs. In this study, we performed 5, 10 ns MD simulations for CP- and OX- DNA adducts, both free in solution and bound to HMGB1a, in the 5'-d(CCTCTGGACTCC)-3' 5\#8217;-d(GGAGTCCAGAGG)-3\#8217; sequence context. CP- and OX-GG adducts in the TGGA sequence context differed in the pattern of hydrogen bond formation between platinum amine hydrogens and the surrounding DNA bases, with CP forming hydrogen bonds (H-bonds) with G7O6 and A8N7, while OX formed H-bonds with G7O6 and T17O4. The snapshots from each trajectory were clustered on the basis of the type of H-bond the drugs formed with surrounding DNA bases. No significant differences were observed between structures associated with the CP- and OX-G7O6 H-bonds. However, the differences in H-bond formation to A8N7 and T17O4 correlated with differences in DNA conformational dynamics that may be important for binding of HMGB1a. For example, structures associated with the CP-A8N7 H-bond differed significantly in twist, slide, shift and roll at the G7A8 base pair (bp) step compared with those associated with the OX-T1704 H-bond. In this case, the conformations associated with the OX-T17O4 H-bond were preferential for H-bond formation between Ser41 of HMGB1a and A8N3. In contrast, the CP-A8N7 H-bond cluster of structures explored a minor conformation for roll at G6G7 bp step that was more favorable for stacking of HMGB1a Phe37 with the 3\#8217;G (G7) than structures associated with the OX-T17O4 H-bond. Furthermore, these differences in roll at the G6G7 bp step were preserved in the simulations of the CP- and OX-DNA-HMGB1a complexes. Previous mutagenesis studies by He et al (Biochemistry, 39: 14426-14435, 2000) showed that the Phe37A mutation had a much stronger effect on DNA binding than the Ser41A mutation. Thus, the effects of CP- and OX-DNA adducts on DNA conformational dynamics are complex, but appear to favor HMGB1a binding to the CP-DNA adduct. In summary, we see significant differences in H-bond patterns between CP- and OX-GG adducts in the TGGA sequence context. These H-bond patterns strongly correlate with differences in DNA conformational dynamics which may influence the ability of damage recognition proteins such as HMGB1a to discriminate between CP- and OX-adducts. (Supported by NIH grant CA84480)

Citation Information: In: Proc Am Assoc Cancer Res; 2009 Apr 18-22; Denver, CO. Philadelphia (PA): AACR; 2009. Abstract nr 4528.

Footnotes

  • 100th AACR Annual Meeting-- Apr 18-22, 2009; Denver, CO

  • American Association for Cancer Research
Back to top
Cancer Research: 69 (9 Supplement)
May 2009
Volume 69, Issue 9 Supplement
  • Table of Contents
  • Index by Author

Sign up for alerts

Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Cancer Research article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Abstract #4528: The effect of conformational dynamics of cisplatin- and oxaliplatin-DNA Adducts on binding of DNA damage recognition proteins such as HMGB1
(Your Name) has forwarded a page to you from Cancer Research
(Your Name) thought you would be interested in this article in Cancer Research.
Citation Tools
Abstract #4528: The effect of conformational dynamics of cisplatin- and oxaliplatin-DNA Adducts on binding of DNA damage recognition proteins such as HMGB1
Srinivas Ramachandran, Brenda Temple, Nikolay Dokholyan and Stephen Chaney
Cancer Res May 1 2009 (69) (9 Supplement) 4528;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Abstract #4528: The effect of conformational dynamics of cisplatin- and oxaliplatin-DNA Adducts on binding of DNA damage recognition proteins such as HMGB1
Srinivas Ramachandran, Brenda Temple, Nikolay Dokholyan and Stephen Chaney
Cancer Res May 1 2009 (69) (9 Supplement) 4528;
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
  • Info & Metrics
Advertisement

Related Articles

Cited By...

More in this TOC Section

Experimental and Molecular Therapeutics

  • Abstract SY14-03: Anaplastic lymphoma kinase (ALK): Normal biology and role in hematopoietic malignancies
  • Abstract SY18-01: Targeting the p53-MDM2 interaction for cancer therapy
  • Abstract SSY01-04: Discovery and validation of genome-wide genetic signatures of chemotherapy susceptibility: A translational model
Show more 3

Agents Causing DNA Damage or Proteasome Inhibition -- Poster Presentations - Proffered Abstracts

  • Abstract #4523: The use of the nucleoside-prodrug EPD-clofarabine (HDP15.0022) in different xenograft models of solid tumors
  • Abstract #4519: Disruption of the thioredoxin system by the anticancer prodrug Laromustine
  • Abstract #4521: G-rich oligodeoxynucleotides inhibit the expression of HIF-1\#945; and HIF-2\#945; and block tumor growth
Show more 3
  • Home
  • Alerts
  • Feedback
Facebook  Twitter  LinkedIn  YouTube  RSS

Articles

  • Online First
  • Current Issue
  • Past Issues
  • Meeting Abstracts

Info for

  • Authors
  • Subscribers
  • Advertisers
  • Librarians
  • Reviewers

About Cancer Research

  • About the Journal
  • Editorial Board
  • Permissions
  • Submit a Manuscript
AACR logo

Copyright © 2018 by the American Association for Cancer Research.

Cancer Research Online ISSN: 1538-7445
Cancer Research Print ISSN: 0008-5472
Journal of Cancer Research ISSN: 0099-7013
American Journal of Cancer ISSN: 0099-7374

Advertisement